The major factors driving the growth of this market include the growing need to curb increasing healthcare costs and a growing focus on patient-centric care delivery. Moreover, government initiatives for enhancing patient care & safety and government funding for healthcare interoperability are also boosting market growth.
The Healthcare Interoperability Solutions Market is expected to reach USD 4.2 billion by 2024 from an estimated USD 2.3 billion in 2019, at a CAGR of 12.6%. Ask for PDF Brochure: –https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17705847 Market Segmentation:- Based on type, the healthcare interoperability solutions market is segmented into software and services. The services segment is estimated to account for the largest market share in 2019. The large share of this segment can be attributed to the shifting era towards cloud computing and reduced operational costs for better and faster performance of business processes and applications. Based on software type, the Interoperability solutions Market is segmented into EHR interoperability solutions, lab system interoperability solutions, imaging system interoperability solutions, HIE interoperability solutions, enterprise interoperability solutions, and other interoperability solutions. The HIE interoperability solutions segment is expected to grow at the highest CAGR during the forecast period. Recent Developments:-
Regional Analysis:- North America is expected to account for the largest share of the Interoperability solutions Market in 2019, followed by Europe. The dominance of the North American region can be attributed to the rising demand for quality healthcare delivery, a need to curb increasing healthcare expenditure, and the implementation of favorable initiatives & regulations to improve the overall efficiency of healthcare organizations in the region. Request for Sample pages :- https://www.marketsandmarkets.com/requestsampleNew.asp?id=17705847 Top Key Players:- The prominent players in the Interoperability solutions Market are Cerner Corporation (US), Infor, Inc. (US), Allscripts Healthcare Solutions, Inc. (US), Koninklijke Philips NV (Netherlands), InterSystems Corporation (US), Orion Health Group Limited (New Zealand), iNTERFACEWARE (Canada), Quality Systems, Inc. (US), OSP Labs (US), Epic Systems Corporation (US), ViSolve, Inc. (US), and Jitterbit (US).
0 Comments
The growth of this market is primarily driven by the increasing global meat demand, research into alternatives to antibiotics, and the need to deal with epidemics and environmental factors. However, various countries have stringent regulations in place against antibiotics and particular growth promoters, which has affected their adoption.
The report Animal Growth Promoters and Performance Enhancers Market is projected to reach USD 18.5 billion by 2024 from an estimated USD 13.9 billion in 2019, at a CAGR of 5.9% during the forecast period. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137134167 Market Segmentations: -. Based on type, the animal growth promoters market is segmented into antibiotic and non-antibiotic growth promoters. The non-antibiotic growth promoters segment accounted for the largest share of the animal growth promoters and performance enhancers market in 2018. On the basis of animal type, the Animal Performance Enhancers Market is segmented into poultry, swine, livestock, aquaculture, and other farm animals (equine, rabbit, camel, deer, yak, and geese). In 2019, the poultry segment accounted for the largest share of the animal growth promoters and performance enhancers market. Critical questions answered in the Report: -
Regional Analysis: - In 2019, the Asia Pacific region accounted for the largest market share of 36.7%, followed by North America (26.1%) in 2018. The largest share of the Asia Pacific region is attributed to the strong animal products industry in this region, high population (generating greater domestic meat demand), a comparatively relaxed regulatory scenario, and government efforts to encourage animal producers. Request for Sample Pages : - https://www.marketsandmarkets.com/requestsampleNew.asp?id=137134167 Key Players: - The key players in the global animal performance enhancers market are Merck and Co. Inc. (US), Cargill Inc. (US), Royal DSM N.V. (Germany), Vetoquinol (France), Bupo Animal Health (SA), Elanco Animal Health Inc. (US), CHR Hansen (UK), Novus International Inc. (US), Associated British Foods (ABF) plc (UK), Alltech Inc. (US), ERBER AG (UK), Archer-Daniels-Midland Company (US), Phibro Animal Health Corporation (US), Kemin Industries (US), SHV (Nutreco) (UK), BASF SE (UK), Lallemond Inc. (Canada), Bluestar Adisseo Company (France), Evonik Industries AG (UK), and Land O Lake Inc.(US). Market growth is primarily driven by factors such as growing production of large molecules and biologics, technological advancements in nanofibers, growth in the generics market, and regulatory mandates for cleanrooms in pharmaceutical production. Other factors supporting market growth include an increase in R&D spending by biopharmaceutical companies to offer a strong biologics pipeline.
The global Pharmaceutical Filtration Market is poised to reach USD 22.71 Billion by 2021 from USD 13.73 Billion in 2016, at a CAGR of 10.6% from 2016 to 2021. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209343847 The global pharmaceutical filtration market is segmented on the basis of product, technique, application, scale of operation, and region. On the basis of product, the pharmaceutical filtration market is segmented into membrane filters, prefilters and depth media filters, cartridge & capsule filters, single-use systems, filter holders, filtration accessories, and other products. In 2016, the membrane filters segment accounted for the largest share of the market. This segment is also expected to register the highest CAGR during the forecast period. The key factor driving the growth of the membrane filters segment is the ease of installation in large and small manufacturing facilities owing to the availability of a variety of pore and surface types. Based on application, the final product-processing segment is expected to register the highest CAGR during the forecast period owing to the rapidly growing biologics and generic drug production coupled with the presence of stringent regulatory guidelines to maintain a clean and safe manufacturing environment. North America accounted for the largest share of the global pharmaceutical filtration market in 2016, followed by Europe. Stringent regulatory guidelines to provide safe drugs is encouraging the use of pharmaceutical filtration products and the presence of a large number of market players are propelling the growth of the North American pharmaceutical filtration market. The Asian region is expected to register the highest CAGR in the forecast period. Growing investments in the biopharmaceutical industry and the rise in contract research and manufacturing organizations in emerging Asian countries are the key factors driving the growth of the Asian market. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=209343847 The pharmaceutical filtration market is dominated by established players such as Merck KGaA (Germany), GE Healthcare (U.S.), Pall Corporation (U.S.), Parker Hannifin Corporation (U.S.), and Sartorius Stedim Biotech S.A. (France). The benefits of CRM software and a growing focus on patient engagement are the major factors driving the growth of the healthcare CRM market.
The report Healthcare CRM Market is projected to reach USD 17.4 billion by 2023 from USD 8.8 billion in 2018, at a CAGR of 14.6% during the forecast period. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=88873203 Market Segmentation: - Based on end user, the healthcare CRM market is segmented into healthcare providers, the life sciences industry, and healthcare payers. The healthcare providers segment is estimated to account for the largest share of the healthcare CRM market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Healthcare providers need to interact with multiple stakeholders, including patients, physicians, other referral healthcare organizations, healthcare payer organizations, pharmaceutical companies, and consumers/potential patients, and each requires unique CRM strategies and solutions. Moreover, there is a growing focus on patient engagement, which is again likely to drive the market for this segment. On the basis of component, the healthcare CRM market is segmented into software and services. The services segment is expected to dominate the healthcare CRM market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Services form a large component of the healthcare CRM market primarily due to the indispensable role of service providers when it comes to the use of CRM solutions for healthcare. In terms of IT usage and skills, the healthcare industry is still in the nascent stage; it relies heavily on service providers for CRM-related services and support services, such as implementation, integration, training and education, maintenance, and technology upgrades. The recurring need for services such as software upgrades and maintenance is the key factor supporting the growth of this segment. Regional Analysis: - Geographically, the global healthcare CRM market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is estimated to hold the largest share of the healthcare CRM market. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=88873203 Top Key Players: - The key players in the healthcare CRM market are Salesforce.com, Inc. (US), SAP SE (Germany), Oracle (US), Microsoft (US), IBM (US), Influence Health (US), SugarCRM (US), Accenture (Ireland), Healthgrades (US), and Infor, Inc. (US). The growth of the market is attributed to the increasing geriatric population and subsequent growth in global disease incidence, favorable regulations and government initiatives & investments, the advantages of digital X-ray systems, and technological advancements and product development.
The Digital X-ray Market is expected to reach USD 13.04 billion by 2023 from USD 8.68 billion in 2018, at a CAGR of 8.5%. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1164 Market Segmentation: - Based on application, the Digital Radiography Market is segmented into general radiography, dental applications, fluoroscopy, and mammography. In 2018, the general radiography segment is expected to account for the largest share of the digital X-ray market. The growth in this market is mainly driven by the rising prevalence of diseases like tuberculosis, osteoporosis, and CVD; growing aging population; and product launches. By technology, the Digital Radiography Market is segmented into direct radiography and computed radiography. The direct radiography segment is expected to register the highest rate during the forecast period. Recent Developments:-
In 2018, North America is expected to dominate the market. The large share of this geographical segment is attributed to factors such strong economies in the US and Canada, which have allowed for significant investments in new technologies. Request for sample Pages :- https://www.marketsandmarkets.com/requestsampleNew.asp?id=1164 Key Players:- The mammography x ray market is highly competitive with the presence of several small and big players. Some of the players in the digital X-ray market are Canon Inc. (Japan), Carestream Health (US), Fujifilm Corporation (Japan), GE Healthcare (US), Hitachi Ltd. (Japan), Hologic, Inc. (US), Philips Healthcare (Netherlands), Shimadzu Corporation (Japan), Siemens Healthineers (Germany), Konica Minolta, Inc. (Japan), Samsung Medison Co., Ltd. (Korea), and Agfa Gevaert (Belgium) Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are propelling the growth of the global stem cell therapy market.
The Stem Cell Therapy Market is expected to reach USD 161.8 million by 2022, growing at a CAGR of 11.0% during the forecast period. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48 Market Segmentation: - On the basis of mode of therapy, the global stem cell therapy market is divided into two major categories, namely, allogeneic stem cell therapy and autologous stem cell therapy. The allogeneic stem cell therapy segment is expected to command the largest share of 95.2% in the global stem cell therapy market in 2017 growing at a CAGR of 11.2% during the forecast period. On the basis of therapeutic application, the global Stem Cell Therapy Industry is segmented into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases, and other applications. The musculoskeletal disorders segment is expected to command the largest share of 61.1% in the global stem cell therapy market in 2017. Furthermore, the CVS diseases segment is expected to grow at the highest CAGR of 13.0% during the forecast period. On the basis of cell source, the global Stem Cell Therapy Industry is divided into adipose derived MSCs, bone marrow derived MSCs, embryonic / cord blood SCs, and other cell sources. The adipose derived MSCs segment was expected to account for the largest share of 59.1% in the global stem cell therapy market in 2017. Market Growth Drivers :- 1 Growing Awareness Related to the Therapeutic Potency of Stem Cells in Effective Disease Management 2 Development of Advanced Genome-Based Cell Analysis Techniques 3 Increasing Public-Private Investments for the Development of Stem Cell Therapies 4 Development in Infrastructure Related to Stem Cell Banking and Processing Regional Analysis:- North America is expected to be the largest regional segment in the global stem cell therapy market in 2017, followed by Asia-Pacific. In addition, the North American stem cell therapy market is expected to be the fastest growing region during the forecast period, growing at a CAGR of 11.5%. Request for Sample Pages :-https://www.marketsandmarkets.com/requestsampleNew.asp?id=48 Key Market Players:- As of 2016, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) were some of the key players operating in the global stem cell therapy market. The key factors driving the growth of this market are the growing prevalence of chronic diseases (such as cancer, diabetes, and cardiovascular diseases), favorable reimbursement scenario in major markets, and technological advancements in injector devices.
The Wearable Injectors Market is projected to reach USD 9.41 billion by 2023 from USD 5.57 billion in 2018, at a CAGR of 11.1% during the forecast period. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=100771004 Market Segmentation:- On the basis of type, the Wearable Injectors Industry is segmented into on-body and off-body injectors. The on-body injectors segment is expected to account for the larger market share in 2018, while the off-body injectors segment is projected to witness the highest growth rate during the forecast period. The drawbacks associated with on-body wearable injectors, such as painful removal, skin sensitivity issues and irritation, and adhesive fitting issues have resulted in the increased adoption of off-body injectors. On the basis of therapy, the wearable injectors market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies (Parkinson’s disease, thalassemia, and primary immunodeficiency disorders). In 2018, the immune-oncology segment is expected to account for the largest share of the wearable injectors market. This can be attributed to the high prevalence of cancer across the globe. Recent Developments:-
Regional Analysis:- In 2018, North America is expected to account for the largest share of the wearable injectors market, followed by Europe. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=100771004 Top Key Players: - The key players in the global Wearable Injectors Industry are Amgen (US), Medtronic (Ireland), Insulet Corporation (US), Tandem Diabetes Care (US), United Therapeutics Corporation (US), Valeritas (US), and SteadyMed Therapeutics (US). The other prominent players in this market are Ypsomed (Switzerland), Becton, Dickinson and Company (US), Enable Injections (US), Sensile Medicals (Switzerland), and Bespak (UK). Key factors such growing geriatric population, increasing number of hospitals in emerging markets, and high prevalence of chronic diseases are the major factors driving the growth of the needles market across the globe.
The Needles Market is expected to reach USD 8.47 Billion by 2022, at CAGR of 7.8% during the forecast period. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223979930 Market Segmentation:- On the basis of type, the global needles market is segmented into two broad categories, namely, conventional needles and safety needles. The conventional needles market is estimated to command the larger share of the global needles market in 2017. The growing demand for biosimilar products, the increasing incidence of chronic disease, and the expanding injectables market are the key factors contributing to the growth of this market segment. Based on product, the market is segmented into suture needles, blood collection needles, ophthalmic needles, dental needles, insufflation needles, pen needles, and other needles. The needles market is segmented into hypodermic, intravenous, intramuscular, and intraperitoneal needles on the basis of delivery mode. The hypodermic needles segment is expected to account for the largest share of the needles market in 2017. Key Market Drivers: – 1 High Prevalence of Chronic Diseases 2 Growing Geriatric Population 3 Increasing Number of Hospitals in Emerging Markets 4 Increasing Demand for Vaccines Regional Analysis: - As of 2016, North America held the largest share of the global needles market, followed by Europe. Its dominant share is attributed to the rising incidence of chronic diseases, initiatives by different organizations for the reduction in blood borne infections and increasing prevalence of cardiovascular diseases. Request for Sample Pages: -https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=223979930 Top Key Players: - The key players in the global needles market are Hamilton Company (U.S.), Medtronic plc (Ireland), Becton, Dickinson and Company (U.S.), Stryker Corporation (U.S.), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (U.S.), Terumo Corporation (Japan), Novo Nordisk A/s (Denmark), Smiths Medical (U.K.), and Thermo Fisher Scientific (U.S.). The major factors driving the growth of the surgical retractors market are increasing number of surgical procedures; market availability of specialized and application specific retraction products; continuous expansion of geriatric population; and rising demand for plastic and reconstructive surgeries.
The report Surgical Retractor Market is projected to reach USD 2.5 billion by 2023 from USD 1.8 billion in 2018, at a CAGR of 7.2%. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121697708 Market Segmentation:- Based on product type, the surgical retractors market is segmented into hand-held retractors, self-retaining retractors, table-mounted retractors, wire retractors, and accessories. The hand-held retractors segment is expected to account for the largest share of the surgical retractors market in 2018. The availability of a wide range of affordable handheld retractors coupled with significant preference of healthcare providers for these products across the world and large number of surgical procedures (especially abdominal and cardiothoracic procedures) conducted across major healthcare markets is the major factor driving the growth of this market segment. Based on applications, the surgical retractors market is segmented into abdominal applications; cardiothoracic applications; orthopedic applications; obstetric and gynecological applications; general surgical applications; head, neck, and spinal applications; aesthetic surgical applications, and other applications. The surgical retractors market for head, neck, and spinal application is expected to witness high growth rate in the during forecast period. Based on end user, the surgical retractors market is segmented into hospitals, clinics, and surgical centers; ambulatory care centers; and maternity and fertility centers. The hospitals, clinics, and surgical center end user segment is expected to account for the largest share during the forecast period. The growing number of surgical procedures across the globe and growth in the number of hospitals, clinics and surgeons providing surgical treatments are the key factors driving the growth of this segment. Regional Analysis: - The surgical retractors market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. The North America region is expected to account for the largest share of the global surgical retractors market in 2018, and this trend is expected to continue during the forecast period. Dominant position of North America is mainly attributed to the high number of surgical procedures in the region, the presence of a well-established healthcare system, and on-going investments by hospitals to upgrade operating rooms (including surgical instruments). Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=121697708 Top key players: - As of 2017, major players operating in the global surgical retractors market are Johnson & Johnson (Us), Medtronic Plc (Us), Becton, Dickinson And Company (Us), Stryker Corporation (Us), Terumo Corporation (Japan), Henry Schein, Inc. (Us), B. Braun Melsungen Ag (Germany), Teleflex Incorporated (Us), Integra Lifesciences Holdings Corporation (Us), The Cooper Companies, Inc. (Us), Globus Medical, Inc. (Us), Rti Surgical, Inc. (US), Arthrex, Inc. (US), Invuity, Inc. (US), And Medline Industries, Inc. (US), Among Others. The rising incidences of chronic and infectious diseases, increasing awareness of health and fitness, as well as major technological advancements are key factors driving the IVD market in the U.S. However, the lack of sufficient budget and reimbursement for novel diagnostic tests are restraining market growth.
The U.S. In Vitro Diagnostics (IVD) Market is projected to reach USD 25.99 Billion in 2020 at a CAGR of 4.7% from 2015 to 2020. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=66290979 The U.S. IVD product & services market is broadly segmented into reagents, instruments, services, and data management software. The reagents segment accounted for the largest share of the U.S. IVD product & service market in 2014 and is expected to grow at a highest CAGR during the forecast period. The large share of this segment is primarily attributed to the accessibility of a wide range of reagents and the need for reliable, specific, and faster detection of chronic diseases and genetic disorders at early stages. On the basis of end user, the U.S. IVD market is segmented into hospital laboratories, clinical/independent laboratories, and others. In 2014, the hospital laboratories segment accounted for the largest share of the U.S. IVD market in the U.S. The high inpatient flow and ancillary outpatient flow in hospitals, increasing prevalence of chronic and infectious diseases, and growing number of accredited laboratories are key factors driving market growth in this end-user segment. The U.S. IVD market has been segmented into four regions namely, South, Midwest, Northeast, and West. In 2014, the South region commanded the largest share of the U.S. IVD market, followed by West. However, the Midwest region is expected to witness the highest growth largely driven by the increasing number of accredited laboratories, reimbursement by the Medicare, increasing demand for technologically advanced diagnosis devices, and growing spending capabilities of consumers on healthcare. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=66290979 Some major players in the U.S. IVD market are Roche Diagnostics Limited (Switzerland), Abbott Laboratories, Inc. (U.S.), Becton, Dickson and Company (U.S.), Johnson & Johnson (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Siemens Healthcare (Germany), Bio-Rad Laboratories, Inc. (U.S.), Sysmex Corporation (Japan), QIAGEN N.V. (Netherlands), Alere Inc. (U.S.), Ortho-Clinical Diagnostics Inc. (U.S.), and bioMérieux (France). |
AuthorWe are providing and consulting the healthcare Industry Research Report. Archives
March 2022
Categories |